INTRODUCTION

CLINICAL SIGNIFICANCE OF QUANTITATIVE HBS ANTIGEN IN THE PREDICTION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B
Hepatitis B viral infection can be manifested as an acute hepatitis, chronic hepatitis, cirrhosis and hepatocellular carcinoma (HCC). [1] The presence of hepatitis B surface antigen (HBsAg) in the serum of the patients for more than six months is a hallmark of chronic hepatitis B viral infection (CHB), and it is estimated that there are more than 350 million of people with chronic hepatitis B infection worldwide. [2, 3] The sequels of CHB are significant and appear in approximately 5 % of infected adult patients which cause 0.5 to 1.2 billion deaths annually.
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Timely discovery of liver fibrosis is of great importance for starting antiviral therapy on time and preventing the late complications of CHB. The golden standard for the assessment of liver fibrosis is liver biopsy, invasive and expensive procedure with possible serious complications. At the same time, the accurate evaluation of fibrosis by liver biopsy is questionable having in mind the possible sampling error, as well as possible inter and intra-observational discrepancies [4] . Transient elastography (TE) is a surrogate marker for liver biopsy in many studies and is an accurate, fast and easy to perform technique. [5] Quantitative HBsAg (HBsQ) is one of the main serologic markers of interest in chronic HBV viral infection, [6] and represents a non-invasive marker for monitoring both disease progression and prognosis as well as response to antiviral therapy. [7, 8, and 9] Several studies have observed the correlation between quantitative HBsAg and liver fibrosis. [10] The aim of this study is to determine the clinical significance of quantitative HBsAg in predicting liver fibrosis.
MATERIAL AND METHODS
The study was conducted at the University Clinic for Infectious Diseases and Febrile Conditions, Skopje and as a prospective study of treatment naïve patients with serologically confirmed chronic hepatitis B viral infections. The patients were diagnosed and controlled at the outpatient clinic for hepatitis. The inclusion criteria were: age over 18 years, patients with signed informed consent, and patients with serologically confirmed hepatitis B surface antigen (HBsAg) in a period of at least ix months, patients who have been observed in at least two occasions, with a minimum period of follow-up of at least 6 months. The exclusion criteria were: co-infection with human immunodeficiency virus (HIV), hepatitis A (HAV) and hepatitis C (HCV) as well as other liver diseases with confirmed different ethology. Patients who had received antiviral therapy, patients who are currently on antiviral therapy, patients with hepatocellular carcinoma (HCC) and patients with decompensated liver disease were also not included in the study. The study included 44 patients, 21 in the group of inactive carriers (IC) defined with the presence of HBsAg in patients' serum for more than 6 months, persistently normal level of alanine aminotransferase (ALT) <40 IU/ ml and HBV DNA <2000 IU/ml and 23 patients with HBeAg negative chronic hepatitis B, defined with HBsAg positivity for more than 6 months, patients who are HBeAg negative, with ALT levels higher than upper reference limit or normal (≥40 IU/ml) and HBV DNA >2000 IU/ml. 
Statistical analysis
All data were processed using a statistical computer program Statistica 7.1 for Windows and SPSS Statistics 17.0, where the following statistical tests were used: the differences between both groups of patients with attributive parameters were tested with the use of the Pearson Chi-square test, the Fisher Exact Test (p). For determining the risk of fibrosis, Odds Ratio/RR was used. Descriptive statistics (Mean; Std. Deviation; ±95.00% CI; Minimum; Maximum) for description of the numerical variables, frequencies and percentages for description of the categorical variables was used. Distribution of the data was tested with the Kolmogorov-Smirnov test; Lilliefors test; Shapiro-Wilks test (p). For testing the difference between the two groups, the analyzed parameters were tested with t-test for independent parameters (t/p), Mann-Whitney U test (Z/p). Correlations between HBsQ & HBV DNA; HBsQ & ALT were done with the use of Spearman Rank Order (R); and Multiple Regression (R) analysis was performed to find the correlation between dependent and independent variables. In order to identify the predictive values for age, gender, ALT, HBsQ, HBV DNA for fibrosis logistic regression analysis (Wald, Exp (B), 95.0% CI for Exp (B), and p) was used. For all analyzes the p value < 0.05 was considered statistically significant.
RESULTS
The study included 44 patients, divided into two groups: 21 patient inactive carriers of hepatitis B (IC) and 23 patients with HBeAg-negative chronic hepatitis B. In the group of IC, 13 (61.90%) were male, and 8 (38.10%) female. age by 1 year, there is a significant increase in the probability for fibrosis by 18.00% (Ext (B) =1.18); 95% C.I. for EXP (B): 1.04-1.33 / p<0.05. The increase of HBsQ for one single unit (IU/ml) doesn't have predictive value for fibrosis (Ext (B) =1.00), 95% C.I. for EXP (B): 1.00-1.00 / p>0.05. Female patients compared to male patients have 0.37 times lesser risk for fibrosis (Ext (B) =0.37), 95% C.I. for EXP (B): 0.03-4.33 / p>0.05. The increase of HBV DNA for one single unit (IU/ ml) has no predictive value for fibrosis (Ext (B) =1.00), 95% C.I. for EXP (B): 1.00-1.00 / p>0.05. The increase of ALT for 1 IU/ml increases the probability for fibrosis for 0.1% (Ext (B) =1,001) insignificantly for 95% C.I. for EXP (B): 0.98-1.02 / p>0.05. The area under the ROC curve is 0.883, which means that in 88.30% of all possible pairs of patients where one patient has fibrosis and the other does not have fibrosis, this model will 
Table 1. Differences between patients IC and HBeAg-negative patients in terms of ALT/HBsQ/ HBV DNA
Abbreviations: ALT-alanine aminotransferase; HBsQ-quantitative hepatitis B antigen; HBV DNA-hepatitis B virus deoxyribonucleic acid; HBeAg (-)-hepatitis Be antigen negative hepatitis; IC-inactive carriers determine higher probability for fibrosis. The correlation between fibrosis as a dependable variable and HBsQ as an independent parameter showed intermediate weak insignificant correlation for R=0.25 (p<0.10). Namely, the increase of HBsQ for one single unit (IU/ml), increases fibrosis insignificantly for 0.00001 units (p>0.05).
DISCUSSION
HBsAg represents a significant prognostic marker in means of disease outcome, not only in the natural history, but also during the antiviral treatment of chronic HBV infection. [9, 11] . Many studies showed that the level of HBsAg (HBsQ) can correlate with the serum level of HBV DNA and at the same time is a surrogate marker of intrahepatic covalently closed circular DNA (cccDNA), which is responsible for virus persistence and is a template for viral replication which can vary in different phases of HBV infection. [12, 13] Quantification of HBsAg gives us different, but complementary information which can help the physician in the evaluation of different phases of chronic HBV infection and disease progression. Chronic HBV infection is characterized with five different phases [14] : 1.HBeAg-positive chronic HBV infection, former initial immune tolerant phase; 2. HBeAg-positive chronic hepatitis B, former immune active phase; 3. HBeAg-negative chronic HBV infection, former inactive carrier state; 4. HBeAg-negative chronic hepatitis B phase and 5. HBsAg-negative phase. These phases are of great importance in means of clinical approach to the patient, the necessity to perform liver biopsy and decision making for in itiating antiviral therapy, but it is not always easy to distinguish between these different pha ses. Distinguishing HBeAg-negative CHB pha se from inactive carrier state is of great importance and not that easy due to their similar laboratory, biochemical and serological profile. This emphasizes the need for including specific, non-invasive diagnostic serologic markers which would both represent liver injury, but at the same time would also be specific and sensitive markers for determining the phases of the chronic HBV infection. Determining liver fibrosis is crucial in management of patients with CHB, and with the introduction of transient elastography as a non-invasive method, an immense simplification in determining liver fibrosis has been made. In the study of Seto it is found that HBsQ ≥25000 IU/ml can predict fibrosis with great certainty but in HBeAg positive patients, while this relation is not so certain in patients with HBeAg-negative CHB [15] . Our study showed that there is intermediate weak insignificant correlation between HBsQ and liver fibrosis in patients with HBeAg-negative CHB. Our study did not include patients with HBeAg positive CHB. The greatest prediction for liver fibrosis has patients' age (Wald=6.51 / p<0.05 (p=0.01), HBsQ (Wald=0.74/p>0.05 (p=0.39), then gender (Wald=0.63/p>0.05 (p=0.43), HBV DNA (Wald=0.19 / p>0.05 (p=0.66), and ALT has the slightest influence. In our study, we made comparison in both groups of patientsthe HBeAg-negative CHB group and the inactive carrier group which showed that the value of HBsQ in patients with HBeAg-negative CHB is higher than in the IC group (Z=3.32, p<0.001) (p=0.0009) as well as the value of HBV DNA (Z=5.67, p<0.001) (p=0.000). The study of Zhu [16] carried out over 124 patients with chronic hepatitis B showed that there is correlation between HBV DNA and serum level of HBsQ in patients with CHB and at the same time this study showed that the level of HBsQ can appropriately reflect the level of HBV DNA replication. Pearson's correlation analysis showed that the serum level of HBV DNA is positively correlated with the serum level of quantitative HBsQ (r=0.657, p=0.000<0.05). In our study we found that in the group of IC there is intermediate strong positive correlation between HBsQ and HBV DNA, Spearman Rank R=0.45 ( p<0.05), while in the HBeAg-negative group there is intermediate weak positive statically insignificant correlation Spearman Rank R=0.31 and p>0.05. In the study of Balkan [17] 204 patients with chronic hepatitis B were investigated, IC and patients with chronic active hepatitis B, and the correlation between HBsQ and HBV DNA, ALT level, liver fibrosis and HAI index was investigated. No correlation was found in the inactive carrier group, but intermediate positive correlation was found in the patients with chronic HBeAg positive hepatitis B [17] . Unlike the Balkan's study, our study did not investigate the correlation between quantitative HBsAg and serum HBV DNA in patients with chronic HBeAg positive hepatitis B, but we found intermediate positive correlation between the investigated parameters in patients with HBeAg-negative chronic hepatitis B, and not in the inactive carrier group. Fibrosis as a form of liver injury is significantly higher in patients with HBeAg-negative chronic hepatitis B compared to IC for Fisher Exact Test p<0.05 (p=0.02). At the same time, patients with HBeAg-negative chronic hepatitis B have 10.67 times greater risk for fibrosis than IC for OR = 10.67 (95% CI: 1.20-94.74). There is intermediate weak statistically insignificant correlation between fibrosis as a dependent incidence and HBsQ as an independent parameter for R=0.25 (p<0.10). Each increase of HBsQ for one single unit (IU/ml) increases fibrosis insignificantly for 0.00001 units (p>0.05) unlike the study of Hong [18] where there is significant correlation. The Hong study showed that there is intermediate strong positive statistically significant correlation between HBsQ and quantitative HBV DNA in the IC group of patients (R=0.45, p<0.05), while in patients with HBeAg negative CHB there is intermediate weak positive statistically insignificant correlation (R=0.31, p>0.05). In the study of Gunal [19] 99 patients with HBeAg-negative chronic hepatitis B were investigated and ALT levels were compared in patients IC and patients with HBeAg-negative chronic hepatitis B, where ALT levels were 25.94±13.06 IU/ml, and 55.54±82.38 IU/ml respectively, showing statistical significance (p= 0.015). This study also showed weak but statistically significant correlation between the level of HBsQ and the ALT level (r=0.283, p=0.005). In patients included in our study, ALT level varies in the interval of 22.00±14.65 IU/ml in the inactive carrier group, while in patients with HBeAg-negative chronic hepatitis B, the ALT level varies in the interval od 57±53 IU/ml. The value of ALT is significantly higher in the latter group of patients (Z=2.89, p<0.01) (p=0.004). Similarly to the study of Gunal, our study also showed that there is intermediate strong positive correlation between HBsQ and the ALT level in patients with HBeAg-negative chron-ic hepatitis B R=0.37( p>0.05), while in the IC group there is weak positive statistically insignificant correlation between HBsQ and ALT for R=0.03 and p >0.05. In the study of Liu [20] it has been found that the level of HBsAg<1000 IU/mL and HBV DNA <2000 IU/mL measured in one point of time give the possibility for determining which patients will stay inactive carriers of hepatitis B with moderate degree of accuracy and they can also predict occurrence of liver cirrhosis, HCC and seroconversion of HBs antigen.
CONCLUSIONS
Transient elastography represents a fast, simple, safe and painless method for determining liver fibrosis. Fibrosis as a form of liver injury is significantly more present in patients with HBeAg-negative chronic hepatitis B compared to inactive carriers. The investigated relationship between fibrosis as a dependent occurrence and HBsQ as an independent parameter showed intermediate weak statistically insignificant correlation. Patients' age and gender had greater influence on fibrosis occurrence. It is important to take all above mentioned variables in determining the risk for fibrosis in both groups of patients. Our study showed that there is intermediate strong positive correlation between HBsQ and HBV DNA in both groups of patients. It is thought that HBsQ reflects serum replication of hepatitis B virus (HBV DNA). Determining the correlation between HBsQ, HBV DNA, correlation of ALT with HBsQ and HBV DNA, HBsQ and liver injury might ensure more precise evaluation of the risk for liver fibrosis in patients with HBeAg-negative chronic hepatitis B and inactive carriers. The evaluation of correlation between HBsQ, HBV DNA and liver injury will also enable proper patient selection, candidates for antiviral treatment for chronic hepatitis B. At the same time, quantification of HBsAg alone, will also define its prognostic value in both disease outcome and treatment. In this way, besides more precise distinction of phases of chronic HBV infection and discriminating patients true inactive carries of hepatitis B virus, quantification of HBsAg can serve as a serologic marker for evaluating treatment outcome as well.
